According to filings with the U.S. Securities and Exchange Commission, Advanced NanoTherapies has raised $31 Million in new Series B funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: S3 Ventures, T45 Fund

About Advanced NanoTherapies
Advanced NanoTherapies, a T45 Labs portfolio company, is developing a differentiated functionalized nanoparticle platform for local, dual-drug delivery during catheter-based interventions. The company’s lead program, SirPlux Duo, establishes a new category in drug-coated balloon (DCB) therapy by actively delivering two synergistic drugs simultaneously to vascular cells, enabling controlled, sustained dual-drug delivery at the lesion site. The technology is exclusively licensed from Cleveland Clinic and is under clinical evaluation in the ADVANCE-DUO study. SirPlux Duo received FDA breakthrough designation and is an investigational device that has not yet been approved for commercial use.

To learn more, visit https://advancednanotherapies.com/
Linkedin: https://www.linkedin.com/company/advanced-nanotherapies/

Contact:
Marwan Berrada-Sounni, Chief Executive Officer
https://www.linkedin.com/in/marwaneberrada/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.